Legal and Regulatory Affairs workshop summary

Implications of the EHA/ELN guidelines for reporting blast percentage. Comment on: "Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel".

Haematologica·2026

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia.

Blood·2024

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

The oncologist·2022

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

The oncologist·2022

cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.

Cytotherapy·2026

The future of clinical trials of mesenchymal stromal cells in acute graft-versus-host-disease.

Cytotherapy·2026

Human mesenchymal stromal cell extracellular vesicles maintain therapeutic miRNA cargo despite exposure to cystic fibrosis bronchoalveolar lavage fluid.

Cytotherapy·2026

Nonviral transposon‑engineered stem cells characterization: dose‑dependency between vector copy number and transgene expression.

Cytotherapy·2026

Isolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma.

Cytotherapy·2026

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Cytotherapy·2026

Distinguishing Between Enforceable and On-The-Books State-Level Abortion Policies Over Time: Findings From a Policy Surveillance Study.

Journal of public health management and practice : JPHMP·2026

Implementing Racial and Social Justice Policies: A Qualitative Study of Three Local U.S. Jurisdictions.

Health equity·2026

A 10-state investigation of AD/ADRD-capable assisted living regulations using a comprehensive dementia care model.

Frontiers in dementia·2026

Changes to determining deprivation of liberty in health settings.

British journal of nursing (Mark Allen Publishing)·2026

Legal infrastructure for transformative AI governance.

Proceedings of the National Academy of Sciences of the United States of America·2026

Police experiences with cannabis legalization and perceptions of broader drug policy reform.

The International journal on drug policy·2026

Related Experiment Videos

Legal and Regulatory Affairs workshop summary

Related Concept Videos

Implications of the EHA/ELN guidelines for reporting blast percentage. Comment on: "Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel".

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia.

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.

The future of clinical trials of mesenchymal stromal cells in acute graft-versus-host-disease.

Human mesenchymal stromal cell extracellular vesicles maintain therapeutic miRNA cargo despite exposure to cystic fibrosis bronchoalveolar lavage fluid.

Nonviral transposon‑engineered stem cells characterization: dose‑dependency between vector copy number and transgene expression.

Isolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma.

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Distinguishing Between Enforceable and On-The-Books State-Level Abortion Policies Over Time: Findings From a Policy Surveillance Study.

Implementing Racial and Social Justice Policies: A Qualitative Study of Three Local U.S. Jurisdictions.

A 10-state investigation of AD/ADRD-capable assisted living regulations using a comprehensive dementia care model.

Changes to determining deprivation of liberty in health settings.

Legal infrastructure for transformative AI governance.

Police experiences with cannabis legalization and perceptions of broader drug policy reform.

Related Experiment Videos

Legal and Regulatory Affairs workshop summary

Related Concept Videos

Related Articles